4,6-dimethyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid | 872001-46-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4,6-dimethyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid
• 英文别名: 4,6-Dimethyl-2-pyridin-4-ylpyrimidine-5-carboxylic acid
• CAS: 872001-46-2
• 化学式: C₁₂H₁₁N₃O₂
• 分子量: 229.238
• InChiKey: VCPOYOLUIKAJMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  76
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,6-dimethyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid 、 (4'-methyl-[1,4']bipiperidinyl-4-yl)diphenylamine 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (4,6-dimethyl-2-pyridin-4-yl-pyrimidin-5-yl)-(4-diphenylamino-4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone
  参考文献：
  名称：

  Orally Bioavailable Competitive CCR5 Antagonists

  摘要：

  The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compounds tested were inactive on rodent CCR5, this series includes compounds that cross-react with the cynomolgus monkey (cyno) receptor. One of these compounds, i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.

  DOI：

  10.1021/jm031046g

文献信息

• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20050277668A1

  公开（公告）日：2005-12-15

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及趋化因子受体结合化合物、药物组合物及其用途。更具体地，本发明涉及趋化因子受体活性的调节剂，优选为CCR5的调节剂。这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护效果。
• [EN] OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSES ANTIVIRAUX HETEROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005121145A3

  公开（公告）日：2006-03-02
• OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1761542B1

  公开（公告）日：2008-01-02
• CHEMOKINE RECEPTOR BINDING COMPOUNDS
  申请人：ANORMED INC.

  公开号：EP1896023A2

  公开（公告）日：2008-03-12
• US7498346B2
  申请人：——

  公开号：US7498346B2

  公开（公告）日：2009-03-03